FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
The Food and Drug Administration (FDA) granted accelerated approval to rucaparib for patients with deleterious…
Browsing: deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer